1-(2-苯基-1，3-噻唑-4-基）乙酮 | 10045-52-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-苯基-1，3-噻唑-4-基）乙酮
• 中文别名: 1-(2-苯基-1,3-噻唑-4-基)-1-乙酮；1-(2-苯基-1，3-噻唑-4-基)乙酮
• 英文名称: 2-Phenyl-4-acetylthiazol
• 英文别名: 1-(2-phenylthiazol-4-yl)ethanone；4-Acetyl-2-phenylthiazole；1-(2-Phenyl-1,3-thiazol-4-yl)ethan-1-one；1-(2-phenyl-1,3-thiazol-4-yl)ethanone
• CAS: 10045-52-0
• 化学式: C₁₁H₉NOS
• 分子量: 203.265
• InChiKey: ZOOGZFPRAKXWKI-UHFFFAOYSA-N

物化性质

• 熔点：
  84 °C
• 沸点：
  353.5±34.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)
• 溶解度：
  16.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2934100090

SDS

Name:	1-(2-Phenyl-1 3-thiazol-4-yl)ethan-1-one 97% Material Safety Data Sheet
Synonym:	4-Acetyl-2-phenylthiazol
CAS:	10045-52-0

Section 1 - Chemical Product MSDS Name:1-(2-Phenyl-1 3-thiazol-4-yl)ethan-1-one 97% Material Safety Data Sheet
Synonym:4-Acetyl-2-phenylthiazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10045-52-0	1-(2-Phenyl-1,3-thiazol-4-yl)ethan-1-o	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 10045-52-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 88 - 90 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H9NOS
Molecular Weight: 203

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10045-52-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2-Phenyl-1,3-thiazol-4-yl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 10045-52-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 10045-52-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 10045-52-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-苯基-1，3-噻唑-4-基）乙酮 在 氢氧化钾 、 selenium(IV) oxide 、 sodium acetate 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 1.0h， 生成 5-(2-Phenyl-4-thiazolyl)-2-thioxo-1,3-thiaselenole
  参考文献：
  名称：

  Shafiee, A.; Anaraki, M.; Bazzaz, A., Journal of Heterocyclic Chemistry, 1986, vol. 23, # 3, p. 861 - 864

  摘要：

  DOI：
• 作为产物：
  描述：

  2-苯基-1,3-噻唑-4-羰酰氯 在 吡啶 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1-(2-苯基-1，3-噻唑-4-基）乙酮
  参考文献：
  名称：

  Rh(iii)-catalyzed cyclization reaction of azoles with alkynes: efficient synthesis of azole-fused-pyridines

  摘要：

  已开发出一种Rh（III）催化的氮杂环与炔烃的环化反应，可在良好至优异的产率下构建杂环并联吡啶。

  DOI：

  10.1039/c5ob01338k

文献信息

• Design, synthesis and fungicidal activity evaluation of novel pyrimidinamine derivatives containing phenyl-thiazole/oxazole moiety
  作者：Zhongzhong Yan、Aiping Liu、Yingcan Ou、Jianming Li、Haibo Yi、Ning Zhang、Minhua Liu、Lu Huang、Jianwei Ren、Weidong Liu、Aixi Hu

  DOI：10.1016/j.bmc.2019.05.029

  日期：2019.8

  Diflumetorim is a member of pyrimidinamine fungicides that possess excellent antifungal activities. Nevertheless, as reported that the activity of diflumetorim to corn rust (Puccinia sorghi) was not ideal (EC50 = 53.26 mg/L). Herein, a series of novel pyrimidinamine derivatives containing phenyl-thiazole/oxazole moiety were designed based on our previous study and the structural characteristics of

  地氟美林是嘧啶胺杀菌剂的成员，具有优异的抗真菌活性。然而，据报道，双氟甲蝶呤对玉米锈病（高粱）的活性并不理想（EC50 = 53.26 mg / L）。在此，根据我们先前的研究和双氟甲草胺的结构特征，设计合成了一系列含有苯基-噻唑/恶唑部分的新型嘧啶胺衍生物，并对其进行了生物测定并进行了生物测定，以发现具有优异抗真菌活性的新型杀菌剂。在这些化合物中，T18具有最佳的杀真菌活性，分别对高粱P.orghi和E. graminis的EC50值为0.93 mg / L和1.24 mg / L，具有明显优于商业杀真菌剂diflumetorim，tebuconazole和flusilazole的防治效果。细胞的细胞毒性结果表明，化合物T18的毒性低于双氟甲蝶呤。此外，DFT计算表明，苯基噻唑/恶唑部分在活性提高中起着不可争辩的作用，这将有助于将来设计和开发更有效的化合物。
• [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION<br/>[FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013163279A1

  公开（公告）日：2013-10-31

  The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• Src kinase inhibitor compounds
  申请人：Merck & Co., Inc.

  公开号：US06498165B1

  公开（公告）日：2002-12-24

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

  嘧啶化合物（化学式I），或其药用可接受的盐、水合物、溶剂合物、晶型和单一对映异构体，以及包括这些化合物的药物组合物，它们是酪氨酸激酶酶的抑制剂，因此在预防和治疗蛋白酪氨酸激酶相关疾病方面具有用处，如免疫疾病、高增殖性疾病和其他认为不当的蛋白激酶作用可能起作用的疾病，如癌症、血管生成、动脉粥样硬化、移植排斥、类风湿性关节炎和牛皮癣。
• PAR4 AGONIST PEPTIDES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130289238A1

  公开（公告）日：2013-10-31

  The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

  本发明提供PAR4激动肽。这些肽对于开发强大的PAR4受体测定方法非常有用。
• 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives
  申请人：Pfizer Inc.

  公开号：US04675186A1

  公开（公告）日：1987-06-23

  6-(1-Acyl-1-hydroxymethyl)penicillanic acid derivatives are useful as antibacterials and/or beta-lactamase inhibitors.

  6-(1-酰基-1-羟甲基)青霉烷酸衍生物可用作抗菌剂和/或β-内酰胺酶抑制剂。